Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
October 14 2022 - 8:00AM
Business Wire
Real-world case studies to be presented by
leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern
University and Dr. Seema A. Nagpal of Stanford University
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces an hour-long
webinar to be held today, October 14 at 1 p.m. Eastern time
featuring case studies presented by leading neuro-oncologists who
have used the company’s CNSide assay in the management of patients
with confirmed or suspected central nervous system metastasis.
Webinar Details
Date: Today, Friday, October 14 Time: 1:00 p.m.
Eastern time (10:00 a.m. Pacific time) Registration:
Participants can pre-register or register at webinar start time
here The webinar will be available live and archived at
www.biocept.com.
About the Speakers
Priya U. Kumthekar, MD is a United Counsel for Neurologic
Subspecialties (UCNS)-certified neuro-oncologist from Northwestern
University and is serving as the principal investigator for
Biocept’s FORESEE clinical study. She is dedicated to patient care
and moving the study of brain tumors forward primarily through her
leadership on clinical trials. Dr. Kumthekar serves in leadership
roles with the National Clinical Trials Network, particularly with
the Alliance for Clinical Trials, and was named as the Alliance’s
national Executive Officer of Neuro-Oncology in 2016. In this role,
she oversees the conception and development of clinical trials from
early phase through registration studies. Dr. Kumthekar is board
certified in neurology and is a member of the American Board of
Psychiatry and Neurology. She received her medical degree from
Northeastern Ohio University. She previously was Chief Resident at
Northwestern University, McGaw Medical Center and has led numerous
trials involving primary and secondary brain tumors.
Seema A. Nagpal, MD is a board-certified neuro-oncologist
and has served as Clinical Associate Professor at Stanford
University since 2012. She treats patients with primary brain
tumors and metastatic disease to the brain and nervous system. Her
research concentrates on clinical trials for patients with
late-stage central nervous system cancer and she has a special
interest in leptomeningeal disease, a devastating complication of
lung and breast cancers. In collaboration with Stanford scientists,
including breast and lung oncologists, Dr Nagpal’s work is focused
on more sensitive disease detection and the improvement of patient
outcomes. She previously was a neuro-oncology fellow at Stanford
hospitals and clinics, and a neurology resident at the University
of California San Francisco. She received her medical degree from
the University of Pennsylvania.
About Biocept Biocept, Inc. develops and commercializes
molecular diagnostic assays that provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with a variety of cancers. Biocept focuses on cancers
that have metastasized into the central nervous system and has
developed its proprietary CNSide™ cerebrospinal fluid assay that
detects metastatic cancer and quantitatively analyzes cerebrospinal
fluid tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221014005094/en/
Investor and Media Contact
LHA Investor Relations Jody Cain Jcain@lhai.com, (310)
691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024